ArticleClinical ophthalmology (Auckland, N.Z.)2012
Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization.
Article in Clinical ophthalmology (Auckland, N.Z.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study.Retina (Philadelphia, Pa.) · 2018Trial
- Anti-vascular endothelial growth factor therapy in uveitis: Bridging inflammation and vascular pathology.Indian journal of ophthalmology · 2026Review
- Successful Management of Refractory toxoplasmosis-related Macular Neovascularization with Intravitreal Faricimab.Acta parasitologica · 2026Article
- Unilateral Vogt-Koyanagi-Harada Disease With Two Distinct Choroidal Neovascular Membranes: A Case Report.Cureus · 2024Article
- Inflammatory Choroidal Neovascular Membranes: Clinical Profile, Treatment Effectiveness, and Visual Prognosis.Journal of ophthalmology · 2021Article
- Favorable clinical outcome with intravitreal aflibercept treatment in a case with bilateral choroidal neovascular membrane and quiescent Vogt-Koyanagi-Harada syndrome.GMS ophthalmology cases · 2020Article
- An update on inflammatory choroidal neovascularization: epidemiology, multimodal imaging, and management.Journal of ophthalmic inflammation and infection · 2018Review
- Intravitreal bevacizumab in treatment of retinal neovascularization from tuberculous retinal vasculitis.International journal of ophthalmology · 2017Article
- Aflibercept for inflammatory choroidal neovascularization with persistent fluid on intravitreal ranibizumab therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the 5-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization.
methodsRetrospective, multicenter, consecutive case series of eight patients with inflammatory ocular neovascularization refractory to standard therapy who were treated with intravitreal bevacizumab and followed for 5 years after first injection. The outcome measures included improvement of best-corrected visual acuity expressed as logarithm of minimum angle of resolution.
resultsMean best-corrected visual acuity significantly improved from 0.58 at baseline (6/23 or 20/76; standard deviation = 0.32) to 0.20 at final assessment (6/10 or 20/32; standard deviation = 0.25) (n = 8; P = 0.02), a gain of 3.8 lines (median: three injections; eight eyes; eight patients). No ocular or systemic complications from intravitreal bevacizumab were noted.
conclusionAt 5 years, intravitreal bevacizumab sustained significant visual improvement in ocular neovascularization due to a variety of inflammatory ocular diseases without major complications after a median of three injections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.